Slide 1: Investor Presentation
Investor Presentation August 2026 © 2026 TriSalus Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution. 1
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. The words “anticipate,” “conti
Slide 3: TriSalus at a Glance
TriSalus at a Glance Improving Drug Delivery Pressure Enabled Drug Delivery (PEDD) infusion improves delivery of therapeutics to HCC, for to Solid Tumors pancreatic cancer, and other solid tumors. High Growth, Significant upside from continued market penetration in the liver embolization market Comm
Slide 4: Tumor Microenvironment Limits Drug in Solid Tumors
Tumor Microenvironment Limits Drug in Solid Tumors High intra-tumoral pressure in solid tumors limits efficient drug delivery to tumor Elevated interstitial fluid pressures reduce movement of fluid from vessel into tissue Limited drug uptake Lymphatic system within tumors is often underdeveloped and
Slide 5: PEDD Opens Collapsed Vessels for Improved Drug Delivery
PEDD Opens Collapsed Vessels for Improved Drug Delivery Angiogram of liver tumor vessels demonstrating Opens collapsed tumor vessels PEDD method in High Pressure Tumors1: Wider than conventional catheter Delivers increased contrast dye Surrogate for therapeutic to tumor Traditional Catheter PEDD Met
Slide 6: Increased Drug Delivery to Tumor Correlates with Improved Survival Rates (OS)
Increased Drug Delivery to Tumor Correlates with Improved Survival Rates (OS) Source: Garin, E. Et al. Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-l
Slide 7: Pressure Enabled Drug Delivery Platform
Pressure Enabled Drug Delivery Platform TriNav® Infusion for Improved Drug Delivery 510(k) product portfolio for vascular access throughout the body except the heart and brain Validated in multiple clinical and HEOR studies Unique HCPCS reimbursement codes (both mapping and treatment) for procedures
Slide 8: TriNav Advance—The Next Revolution in PEDD
TriNav Advance*—The Next Revolution in PEDD Advance is a large-lumen device designed to facilitate selective therapy delivery to small, distal vessels via a microcatheter. With the SmartValve placed more proximally, TriNav Advance still improves the T:N Ratio and offers the benefits of PEDD. Telesco
Slide 9: Complete Product Offering to Support IR Liver Embolization
Complete Product Offering to Support IR Liver Embolization 2026 will focus on market penetration with a complete portfolio (*) December ’24 launch June ’25 launch November ’25 launch Pending FDA Clearance Standard Lobar Tortuous Larger Selective Embolization Embolization Anatomy Particles Embolizati
Slide 10: TriNav Infusion System Portfolio
TriNav® Infusion System Portfolio A portfolio of tools to address a wide range of vessel anatomy Thyroid Artery Uterine Artery Genicular Artery Liver (1) Embolization (1) Embolization (1) Embolization (1) 2026E ~$480 million ~$400 million ~$200 million ~$800 million Market Key Products Future TAE Gu
Slide 11: Landmark Real-World Evidence: PEDD Improves Health & Economic Outcomes
Landmark Real-World Evidence: PEDD Improves Health & Economic Outcomes Largest PEDD Study Ever Published, +1,200 Patients Propensity Matches Cohorts (603 TriNav vs 603 non-TriNav patients) Real-World Data Supports TriNav® Treatment in Complex Liver Cancer(1) Sicker patients. Better outcomes. Lower c
Slide 12: TriSalus Specific Procedural Reimbursement for PEDD
TriSalus Specific Procedural Reimbursement for PEDD Procedure code secures long-term access for TriSalus technology PEDDTM Specific Simulation Code PEDDTM Specific Specific Code Private Payer Patients CMS issued New CMS HCPCS CMS issued HCPCS procedural Commercial payers generally follow Code (C8004
Slide 13: Focused Call Point Fuels Standard of Care Momentum for Locoregional Delivery
Focused Call Point Fuels Standard of Care Momentum for Locoregional Delivery Growth Drivers Targeting ~400 hospitals vast majority of procedure volume Expanded Clinical Evidence HEOR Data Expanded Mapping Reimbursement Targeting ~450 of 1,000 Interventional Radiologists who perform embolizations Lau
Slide 14: Central Access Point for Full Value of Platform Portfolio
Central Access Point for Full Value of Platform Portfolio Single, Accessible Hospital Call Point Representing Multiple Indications Liver Tumors (~62K patients) Multinodular Goiter (~50K patients) Uterine Fibroid Embolization (~25K Patients) Genicular Artery Embolization (~100K Patients) Prostate Emb
Slide 15: Combined U.S. PEDD TAM Estimated ~$2.5B Annually
Combined U.S. PEDD TAM Estimated ~$2.5B Annually Efficient expansion opportunity with minimal spend on R&D, Salesforce Indication(s) # Patients1 Market Access Timing Liver (HCC + Colorectal Liver Mets + Neuro ~$480M Endocrine) 62,0002,3,4 Current Multinodular Goiter ~$400M 50,0003 Adjacent Uterine F
Slide 16: Addressable Markets
Addressable Markets © 2026 TriSalus Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution. 16
Slide 17: Multinodular Goiter: ~$400 million U.S. Market Opportunity
Multinodular Goiter: ~$400 million U.S. Market Opportunity High unmet need for minimally invasive treatment option for Multinodular Goiter ~5% of population affected TriNav® Infusion System offers potential alternative to Current Standard of Care Risk factors Iodine deficiency Female sex Metabolic s
Slide 18: TriNav has Potential to be Standard of Care for Treatment of Multinodular Thyroid Disease
TriNav® has Potential to be Standard of Care for Treatment of Multinodular Thyroid Disease TriNav® enables treatment of the entire gland through the inferior thyroid arteries potentially reducing complication of stroke Radioiodine Embolization Ablation Surgery Therapy with PEDDTM Recurrent Potential
Slide 19: Uterine Fibroid Care: ~$200 million U.S. Market Opportunity
Uterine Fibroid Care: ~$200 million U.S. Market Opportunity Significant unmet need to improve fibroid targeting, reduce ovarian off target embolization and post operative pain U.S. Market characterized by high unmet ~10% of population affected need with continued expected growth1,2 Women 18-65 live
Slide 20: Genicular Artery Embolization: ~$800 million U.S. Market Opportunity
Genicular Artery Embolization: ~$800 million U.S. Market Opportunity U.S. Market1 Opportunity Population Affected Anticipated to grow to ~167,000 by 2030 37 % Patients over 60 experience chronic pain due to Significant opportunity to reduce pain, improve OA of the knee1 mobility and delay need for t
Slide 21: Locally Advanced Pancreatic Cancer: ~$400 Million U.S. Market Opportunity
Locally Advanced Pancreatic Cancer: ~$400 Million U.S. Market Opportunity High unmet need for improved treatments Significant Unmet Clinical Need Locally Advanced Adenocarcinoma ~30-50% patients ineligible for surgery Current Standard of Care Multi-agent chemotherapy primary treatment for most patie
Slide 22: Overview of PERIO trials & Investigator Initiated Studies with Nelitolimod
Overview of Pressure-enabled regional immuno-oncology (PERIO) trials & Investigator Initiated Studies with Nelitolimod Seeking Partnership INDICATION TRIAL DESIGN PHASE 1 PHASE 2 PHASE 3 STATUS PERIO – 1: 1a Enrollment concluded Uveal Melanoma Nelitolimod + Phase 1/1b PEDD HAI + CPI Data Release Q12
Slide 23: TriSalus at a Glance
TriSalus at a Glance Financial Highlights NASDAQ Ticker TLSI Shares Outstanding* ~61.6 million common shares outstanding March 31, 2026 Cash Balance $46.3 Million 2026 Outlook Annual revenues in the range of $54 - $57 million *In July 2025, simplified capital structure through the successful complet
Slide 24: Multi-Layered Patents and Exclusivity Provides Long Term Protection
Multi-Layered Patents and Exclusivity Provides Long Term Protection Overview of Parent Multi-Layered Protection and Market Exclusivity between PEDD Portfolio 2030-2040 82 PEDD Devices Registered Patents* PEDD Platform IP 111 PEDD Device & Drug Class IP Methods of Treatment (MoT): New Indications, Co
Slide 25: Executing Against Strategic Priorities
Executing Against Strategic Priorities 2025 Accomplishments Granted unique HCPCS code C8004 for Mapping (Q1) Launch of TriNav FLX (Q2) Completed Preferred Share Conversion (3Q) Initiated Genicular Artery Embolization Study (3Q-4Q) Initiated Uterine Artery Embolization Study (3Q) Launched
Slide 26: Veteran Industry Leadership
Veteran Industry Leadership MARY SZELA DAVID PATIENCE RICHARD JENNIFER STEVENS JODI DEVLIN BRYAN COX, PHD RICHARD CEO & President Chief Financial MARSHAK, VMD Chief Regulatory Chief of Clinical Chief of Research MARSHALL, MD Officer Chief Commercial Officer Strategy & Operations Chief Medical Office
Slide 27: trisaluslifesciences.com
t r i s a l u s l i f e s c i . c o m © 2026 TriSalus Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution. 27